Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia
Perez-Calahorra, S. (Universidad de Zaragoza) ; Laclaustra, M. ; Marco-Benedí, V. ; Lamiquiz-Moneo, I. (Universidad de Zaragoza) ; Pedro-Botet, J. ; Plana, N. ; Sanchez-Hernandez, R.M. ; Amor, A.J. ; Almagro, F. ; Fuentes, F. ; Suarez-Tembra, M. ; Civeira, F. (Universidad de Zaragoza)
Resumen: Background and aims: The impact on heterozygous familial hypercholesterolemia (HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and the question remains if there is still an unacceptably high residual risk to justify treatment with new lipid-lowering drugs.
Methods: This observational, retrospective, multicenter, national study in Spain, whose information was obtained from a national dyslipemia registry, was designed to establish the current prevalence of cardiovascular disease (CVD) in HeFH and to define the impact of HILLT on CVD in this population. Odds were estimated using several logistic regression models with progressive adjustment.
Results: 1958 HeFH, mean age 49.3 ± 14.3 years, were included in the analysis. At inclusion in the registry, 295 patients (15.1%) had suffered CVD and 164 (55.6%) had suffered the first event before the onset lipid-lowering treatment. Exposition to treatment associated more than ten times lower odds for CVD than in subjects naïve to treatment (OR 0.085, 95% CI 0.063–0.114, p < 0.001). A first CVD event after a mean treatment period of 9.1 ± 7.2 years occurred in 131 out of 1615 (8.1%) HeFH subjects, and 115 (87.8%) of them were on HILLT.
Conclusions: Current prevalence of CVD among HeFH is one third of that reported before the statins era. Early initiation and prolonged lipid-lowering treatment was associated with a reduction in CVD. New cases of CVD, in spite of HILLT, appeared mostly among patients accumulating risk factors and probably they may be considered for further lipid-lowering drugs.
Idioma: Inglés
DOI: 10.1016/j.atherosclerosis.2019.02.003
Año: 2019
Publicado en: Atherosclerosis 284 (2019), 245-252
ISSN: 0021-9150
Factor impacto JCR: 3.919 (2019)
Categ. JCR: PERIPHERAL VASCULAR DISEASE rank: 16 / 65 = 0.246 (2019) - Q1 - T1
Categ. JCR: CARDIAC & CARDIOVASCULAR SYSTEMS rank: 42 / 138 = 0.304 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.515 - Cardiology and Cardiovascular Medicine (Q1)
Financiación: info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI15-01983
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Área Enfermería (Dpto. Fisiatría y Enfermería)
Área (Departamento): Area Anatom.Embriol.Humana (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2024-01-16-08:32:26)
Visitas y descargas
Methods: This observational, retrospective, multicenter, national study in Spain, whose information was obtained from a national dyslipemia registry, was designed to establish the current prevalence of cardiovascular disease (CVD) in HeFH and to define the impact of HILLT on CVD in this population. Odds were estimated using several logistic regression models with progressive adjustment.
Results: 1958 HeFH, mean age 49.3 ± 14.3 years, were included in the analysis. At inclusion in the registry, 295 patients (15.1%) had suffered CVD and 164 (55.6%) had suffered the first event before the onset lipid-lowering treatment. Exposition to treatment associated more than ten times lower odds for CVD than in subjects naïve to treatment (OR 0.085, 95% CI 0.063–0.114, p < 0.001). A first CVD event after a mean treatment period of 9.1 ± 7.2 years occurred in 131 out of 1615 (8.1%) HeFH subjects, and 115 (87.8%) of them were on HILLT.
Conclusions: Current prevalence of CVD among HeFH is one third of that reported before the statins era. Early initiation and prolonged lipid-lowering treatment was associated with a reduction in CVD. New cases of CVD, in spite of HILLT, appeared mostly among patients accumulating risk factors and probably they may be considered for further lipid-lowering drugs.
Idioma: Inglés
DOI: 10.1016/j.atherosclerosis.2019.02.003
Año: 2019
Publicado en: Atherosclerosis 284 (2019), 245-252
ISSN: 0021-9150
Factor impacto JCR: 3.919 (2019)
Categ. JCR: PERIPHERAL VASCULAR DISEASE rank: 16 / 65 = 0.246 (2019) - Q1 - T1
Categ. JCR: CARDIAC & CARDIOVASCULAR SYSTEMS rank: 42 / 138 = 0.304 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.515 - Cardiology and Cardiovascular Medicine (Q1)
Financiación: info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI15-01983
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Área Enfermería (Dpto. Fisiatría y Enfermería)
Área (Departamento): Area Anatom.Embriol.Humana (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2024-01-16-08:32:26)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2020-02-17, última modificación el 2024-01-16